Citizens Jmp Issues Pessimistic Forecast for Bicycle Therapeutics (NASDAQ:BCYC) Stock Price

Bicycle Therapeutics (NASDAQ:BCYC) had its price target reduced by equities researchers at Citizens Jmp from $12.00 to $8.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would indicate a potential upside of 75.82% from the stock’s previous close.

A number of other equities research analysts also recently commented on BCYC. Morgan Stanley reiterated a “sell” rating and set a $13.00 price objective on shares of Bicycle Therapeutics in a research report on Tuesday. Needham & Company LLC cut their target price on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Truist Financial set a $8.00 price target on Bicycle Therapeutics in a research report on Tuesday. Finally, Jefferies Financial Group raised Bicycle Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $14.50.

Bicycle Therapeutics Price Performance

NASDAQ BCYC opened at $4.55 on Wednesday. Bicycle Therapeutics has a 12 month low of $4.47 and a 12 month high of $9.86. The company has a market capitalization of $315.63 million, a P/E ratio of -1.44 and a beta of 1.65. The company’s 50 day simple moving average is $5.83 and its 200 day simple moving average is $6.78.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Tuesday, March 17th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.71. The firm had revenue of $47.96 million during the quarter, compared to analysts’ expectations of $7.08 million. Bicycle Therapeutics had a negative net margin of 301.66% and a negative return on equity of 33.21%. On average, analysts anticipate that Bicycle Therapeutics will post -3.06 earnings per share for the current year.

Insider Activity at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 10,989 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.46, for a total transaction of $70,988.94. Following the sale, the chief executive officer directly owned 618,996 shares of the company’s stock, valued at $3,998,714.16. The trade was a 1.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Alethia Young sold 4,334 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the completion of the sale, the chief financial officer owned 87,081 shares of the company’s stock, valued at $565,155.69. The trade was a 4.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 38,029 shares of company stock worth $251,966. Corporate insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Bicycle Therapeutics

Several hedge funds have recently bought and sold shares of the business. Fcpm Iii Services B.V. boosted its position in Bicycle Therapeutics by 0.5% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,468,430 shares of the company’s stock worth $24,556,000 after acquiring an additional 16,100 shares during the period. Armistice Capital LLC increased its holdings in shares of Bicycle Therapeutics by 8.7% in the 4th quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock valued at $22,911,000 after purchasing an additional 258,000 shares during the period. Westfield Capital Management Co. LP lifted its position in shares of Bicycle Therapeutics by 2.2% in the fourth quarter. Westfield Capital Management Co. LP now owns 3,016,026 shares of the company’s stock worth $21,353,000 after purchasing an additional 63,483 shares in the last quarter. GSK plc acquired a new stake in shares of Bicycle Therapeutics during the fourth quarter worth approximately $10,829,000. Finally, Long Focus Capital Management LLC boosted its holdings in shares of Bicycle Therapeutics by 7.7% during the third quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock worth $10,981,000 after purchasing an additional 101,402 shares during the period. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics News Roundup

Here are the key news stories impacting Bicycle Therapeutics this week:

• Positive Sentiment: Oppenheimer cut its price target from $44 to $36 but maintained an “outperform” rating—still implying large upside from current levels. Read More.
• Positive Sentiment: Needham lowered its target from $24 to $15 but kept a “buy” rating, signaling continued analyst conviction despite the reduction. Read More.
• Positive Sentiment: Citizens JMP trimmed its target from $12 to $8 and kept a “market outperform” view, which supports a constructive medium‑term outlook. Read More.
• Neutral Sentiment: Royal Bank of Canada lowered its target from $11 to $7 and set a “sector perform” rating—more neutral guidance relative to prior coverage. Read More.
• Negative Sentiment: Multiple short‑interest notices flagged a “large increase” in short interest for March, although the published figures show zero shares (likely a data/reporting inconsistency). Still, headlines alone can prompt selling or caution among investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.